Table 1. Ivosidenib Phase I Trial Treatment Arms.

Treatment arm	Patient qualification
1	Relapsed after HCT, second or later relapse, resistance to initial induction, reinduction treatment, relapsed within 1 year of initial treatment
2	Untreated patients with AML
3	Advanced hematologic malignancies, including myelodysplastic syndrome
4	Relapsed or refractory AML not eligible for Arm 1

Note. HCT = hematopoietic stem cell transplant; AML = acute myeloid leukemia. Information from DiNardo et al. (2017).